Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + arsenic trioxide
- Development stage
- Unknown
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Sintilimab + arsenic trioxide is an investigational combination therapy being evaluated for the treatment of advanced intrahepatic cholangiocarcinoma (ICC). Sintilimab is a recombinant humanized IgG4 monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, thereby restoring T-cell antitumor activity. Arsenic trioxide (ATO) is a small molecule that induces apoptosis in cancer cells and has been shown to modulate the tumor microenvironment, potentially enhancing the efficacy of immune checkpoint inhibitors by inhibiting angiogenesis and inducing reactive oxygen species. This combination is being pioneered by researchers at the Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) to address the poor prognosis and limited treatment options for ICC.
- Other names
- sintilimab and arsenic trioxidesintilimab/arsenic trioxide
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PML-RARA (PML-retinoic acid receptor alpha fusion protein)TXNRD2 (Thioredoxin reductase 2)
Beyond the preview
Go deeper on sintilimab + arsenic trioxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + arsenic trioxide.